MedTrace Logo

Non-interventional Study of Therapy for Threatened Miscarriage

NCT03309735 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1241

Last updated 2018-01-18

No results posted yet for this study

Summary

Study the efficacy and safety of therapy for threatened miscarriage with medicinal products Utrogestan (micronized progesterone), 200 mg capsules (Besins Healthcare SA, Belgium), and Duphaston (Dydrogesterone), 10 mg coated tablets (Abbott Healthcare Products B.V., the Netherlands)

Conditions

  • Threatened Miscarriage

Interventions

DRUG

Micronized progesterone

Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed

DRUG

Micronized progesterone

Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed

DRUG

Dydrogesterone

Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear

Sponsors & Collaborators

  • Clinical Research Laboratory, CRO, Russia

    collaborator UNKNOWN

  • Besins Healthcare

    lead INDUSTRY

Principal Investigators

  • Igor Manuhin, PhD · Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2017-12-22
Completion
2017-12-22

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309735 on ClinicalTrials.gov